Lv6
1650 积分 2025-11-14 加入
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan
1天前
求助中
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
1天前
已完结
A modular framework for antibody–drug conjugate biomarkers
18天前
已完结
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
19天前
已完结
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
27天前
已完结
An updated patent review of BRD4 degraders
27天前
已完结
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
27天前
已完结
Targeted protein degradation: from mechanisms to clinic
27天前
已完结
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan
27天前
已关闭
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
27天前
已完结
皖公网安备34019202002308
